PortfoliosLab logoPortfoliosLab logo
CGON vs. CMRE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CGON vs. CMRE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CG Oncology, Inc (CGON) and Costamare Inc. (CMRE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CGON achieves a 58.31% return, which is significantly higher than CMRE's -1.48% return.


CGON

1D
-0.78%
1M
2.30%
YTD
58.31%
6M
64.12%
1Y
156.16%
3Y*
5Y*
10Y*

CMRE

1D
0.59%
1M
-6.58%
YTD
-1.48%
6M
-0.66%
1Y
74.98%
3Y*
35.69%
5Y*
16.05%
10Y*
14.11%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CGON vs. CMRE - Yearly Performance Comparison


2026 (YTD)20252024
CGON
CG Oncology, Inc
58.31%44.77%-1.10%
CMRE
Costamare Inc.
-1.48%73.07%18.98%

Correlation

The correlation between CGON and CMRE is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Jan 25, 2024

0.18

Fundamentals

Market Cap

CGON:

$5.56B

CMRE:

$1.85B

EPS

CGON:

-$1.61

CMRE:

$2.87

PS Ratio

CGON:

1.02K

CMRE:

2.17

PB Ratio

CGON:

5.09

CMRE:

0.86

Total Revenue (TTM)

CGON:

$5.07M

CMRE:

$849.60M

Gross Profit (TTM)

CGON:

-$2.54M

CMRE:

$495.90M

EBITDA (TTM)

CGON:

-$191.51M

CMRE:

$569.59M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CGON vs. CMRE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CGON
CGON Risk / Return Rank: 9393
Overall Rank
CGON Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
CGON Sortino Ratio Rank: 9494
Sortino Ratio Rank
CGON Omega Ratio Rank: 9090
Omega Ratio Rank
CGON Calmar Ratio Rank: 9494
Calmar Ratio Rank
CGON Martin Ratio Rank: 9595
Martin Ratio Rank

CMRE
CMRE Risk / Return Rank: 9090
Overall Rank
CMRE Sharpe Ratio Rank: 9292
Sharpe Ratio Rank
CMRE Sortino Ratio Rank: 8989
Sortino Ratio Rank
CMRE Omega Ratio Rank: 8585
Omega Ratio Rank
CMRE Calmar Ratio Rank: 9292
Calmar Ratio Rank
CMRE Martin Ratio Rank: 9292
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CGON vs. CMRE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CG Oncology, Inc (CGON) and Costamare Inc. (CMRE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CGONCMREDifference
Sharpe ratioReturn per unit of total volatility

+0.38

Sortino ratioReturn per unit of downside risk

+0.66

Omega ratioGain probability vs. loss probability

1.41

1.35

+0.07

Calmar ratioReturn relative to maximum drawdown

5.73

5.15

+0.58

Martin ratioReturn relative to average drawdown

17.66

13.70

+3.96

CGON vs. CMRE - Sharpe Ratio Comparison

The current CGON Sharpe Ratio is 2.73, which is comparable to the CMRE Sharpe Ratio of 2.35. The chart below compares the historical Sharpe Ratios of CGON and CMRE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CGON vs. CMRE - Drawdown Comparison

The maximum CGON drawdown since its inception was -67.47%, smaller than the maximum CMRE drawdown of -78.24%. Use the drawdown chart below to compare losses from any high point for CGON and CMRE.


Loading charts...

Drawdown Indicators


CGONCMREDifference

Max Drawdown

Largest peak-to-trough decline

-67.47%

-78.24%

+10.77%

Max Drawdown (1Y)

Largest decline over 1 year

-27.41%

-14.63%

-12.78%

Max Drawdown (3Y)

Largest decline over 3 years

-50.07%

Max Drawdown (5Y)

Largest decline over 5 years

-52.88%

Max Drawdown (10Y)

Largest decline over 10 years

-66.54%

Current Drawdown

Current decline from peak

-11.18%

-13.78%

+2.60%

Average Drawdown

Average peak-to-trough decline

-25.77%

-33.42%

+7.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.88%

5.49%

+3.39%

Volatility

CGON vs. CMRE - Volatility Comparison

CG Oncology, Inc (CGON) has a higher volatility of 16.34% compared to Costamare Inc. (CMRE) at 9.37%. This indicates that CGON's price experiences larger fluctuations and is considered to be riskier than CMRE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CGONCMREDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.34%

9.37%

+6.97%

Volatility (6M)

Calculated over the trailing 6-month period

42.03%

23.81%

+18.22%

Volatility (1Y)

Calculated over the trailing 1-year period

57.56%

32.16%

+25.40%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

66.48%

38.40%

+28.08%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

66.48%

44.34%

+22.14%

Dividends

CGON vs. CMRE - Dividend Comparison

CGON has not paid dividends to shareholders, while CMRE's dividend yield for the trailing twelve months is around 3.00%.


PositionTTM20252024202320222021202020192018201720162015
CGON
CG Oncology, Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
CMRE
Costamare Inc.
3.00%2.54%3.58%4.42%9.11%3.40%4.83%4.20%9.11%6.93%17.32%11.04%

Financials

CGON vs. CMRE - Financials Comparison

This section allows you to compare key financial metrics between CG Oncology, Inc and Costamare Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
1.08M
201.56M
(CGON) Total Revenue
(CMRE) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CGON and CMRE have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CGON has higher volatility (16.34%) compared to CMRE (9.37%). In terms of maximum drawdown, CGON dropped -67.47% vs CMRE's -78.24%.

CGON currently has the higher Sharpe Ratio (2.73 vs 2.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CGON and CMRE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer